VERU INC.
No enriched coverage for $VERU in the last 7 days.
No SEC Form 4 filings for $VERU in the last 30 days.
Veru Inc. has enrolled the first patient in its Phase 2b PLATEAU clinical trial, investigating enobosarm in combination with semaglutide (Wegovy) for high-quality weight loss in older obese patients. The study aims to preserve lean mass, physical function, and bone while augmenting fat loss. Interim data is expected in Q1 2027, with final topline data anticipated in Q4 2027.
MIAMI, FL, Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Veru Inc. ( NASDAQ:VERU ) , a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the presentation of two abstracts at ObesityWeek ...
CINCINNATI, OH, Sept. 26, 2025 ( GLOBE NEWSWIRE ) -- Onconetix, Inc. ( Nasdaq: ONCO ) ( "Onconetix" or the "Company" ) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, announced the ...
